High Content Imaging as an Early Discovery Tool

Applying high content imaging at the earliest stages of drug discovery can provide insights at the very start of your program for those go no go decisions. HCS identifies the interaction of target and compounds within their true physiological state. HCA monitors compound interactions in complex cellular systems can best predict translational success in vivo.

HCA to improve translation to the clinic

Nuclear translocation assayHigh content analysis to screen and profile small molecules.
Download Now

High Content Screening (HCS)

HCS uses a high-throughput live cell imaging format to screen compounds in complex cellular systems to identify new drug targets or new lead compounds. The use of imaging for screening provides more predictive data than the one-end point data usually associated with classic plate-reader high-throughput screening (HTS). This HCS format provides data specifically at the target site as well as any off-target effects all in the same assay. The ability to multiplex allows for monitoring multiples nodes in a cellular pathway at the earliest stages of drug discovery.

Our extensive experience in high-throughput screening, in-house image analysis algorithm design and disease biology allows us to make the right selection of cell type and assay parameters before initiating HCS. We develop assays for small molecule screening using our 850,000 compound collection and for RNAi screening using our proprietary adenoviral platform, SilenceSelect®.

Assay Development: We have developed successful screens that include apoptosis, protein phosphorylation, receptor degradation, marker expression and many more.

High Content Analysis (HCA)

HCA can be used to further profile your compound in disease relevant cell-based assays to optimize lead compounds identified through HTS and HSC. Using live cell imaging to study therapeutics in a complex cellular system, maintains true of cellular physiology provides valuable predictive and translatable data. HCA monitors phenotypic changes such as morphology, cellular localization and proliferation that can be both visualized and quantified and in real time. HCA has progressed to include multicellular structures such as 3D spheroids and co-cultures as well as multiplexing to monitor multiple features within a microenvironment all in one well.

High Content Imaging Assay Development

What to consider

Instrumentation: We have access to and expertise using GE InCell Analyzer 2200 , GE InCellAnalyzer 6000, TTP LabTech Acumen Explorer™, BD Pathway™ 435, LI-COR Odyssey imager, 10 TB and 30 TB dedicated image servers, IncuCtye®.

Cell Types: We have developed successful assays using patient derived tissues and cells ( both healthy and with disease characteristics) Stem cells (hESC, iPSC), human primary cells and genome engineered cells using CRISPR/Cas9 gene editing

Assay type: Our validated assays include but not limited to, Anchorage independence (in 3D), Apoptosis, Autophagy and protein aggregation, Cell motility and migration, Epigenetic modifications, Marker expression, Protein acetylation and phosphorylation, Receptor internalization and degradation, Sub-cellular localization and Translocation of transcription factors.

Thinking about HCS?

High Content Imaging Frequently Asked Questions (FAQs)

  • What’s the difference between HCI, HSC, and HCA?

    The terms high content imaging (HCI), high content screening (HSC), and high content analysis (HCA) are often used interchangeably. HCI refers to the technology, the ability to image. HSC typically refers to screening targets and compounds in a high-throughput format. HCA is studying cell based-assays using HCA, typically for optimizing the hits from a HTS or HCS.

  • Where can HCI be applied in the drug discovery pipeline?

    HCI can be applied to many steps in the drug discovery workflow. At the earliest stage, cellomics and hit identification through high content screening. Once a hit has been identified, that compound can lead can be optimized using HCA which will provide predictive, translatable data for in vivo studies. HCA can also be applied to ex vivo studies before moving into safety assessment. HCI has many applications in well planned integrated drug discovery program.

    CRISPR-Cas9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.

CRISPR-Cas9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.